Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger RNA -- best known for being used in Covid-19 vaccines -- in the hopes of ...
The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.
The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...
The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.
For the last several months, reports about bird flu have largely quieted -- until now. In the first human bird flu case in the U.S. since February, an older adult in Washington state was hospitalized ...
Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.
Morning Overview on MSN
A nanoparticle vaccine shows promise for preventing cancer
Cancer vaccines have long sounded like science fiction, but a new wave of nanoparticle research is pushing that idea closer ...
Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...
New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network ...
MedPage Today on MSN
mRNA Flu Vaccine Tops Standard Shot in Trial
For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those ...
Invivyd, Inc. advances VYD2311 as a Covid-19 vaccine alternative. Learn about upcoming trials and market opportunities. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results